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Abstract 
Traditional research in the health sciences has involved control and experimental groups of patients, and descriptive 
and inferential statistical analyses performed on the measurements obtained from the samples in each group. As 
the novel model of translational healthcare, which integrates translational research and translational effectiveness, 
becomes increasingly established in modern contemporary medicine, healthcare continues to evolve into a model of 
care that is evidence-based, effectiveness-focused and patient-centered. Patient-centered care and patient-targeted 
therapies require the timely and critical development and validation of a new research paradigm, individual patient 
research (IPR), as opposed to the customary group research approach. Here, we propose a model of individual patient 
research to define and characterize the effectiveness of a novel therapeutic intervention for temporomandibular joint 
disorder. The intervention must be tailor-made for each individual patient, and the data from each patient must be 
analyzed individually. We propose that this endeavor is best achieved by means of an adaptive cluster randomized 
stepped wedge blinded controlled trial, because it permit individual patient outcomes research and analysis, ensures 
equipoise, and maintains adequate power. The patient targeted therapies section of the Journal of Translational 
Medicine must endeavor to facilitate the dissemination of studies that focus broadly on translational research for the 
ultimate benefit of individual patients.
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Individual patient data (IPD) in translational 
science
Patient-centered therapies are at the heart of transla-
tional science in healthcare, which has gained consider-
able momentum from the Affordable Care Act-2010. 
In his recent paper [1] in the Journal of the American 
Medical Association, President Obama wrote that “The 
Affordable Care Act is the most important health care 
legislation enacted in the United States since the creation 
of Medicare and Medicaid in 1965. The law implemented 
comprehensive reforms designed to improve the accessibil-
ity, affordability, and quality of health care.” That is cer-
tainly true. It is also a fact that the Affordable Care Act 
leaves many important questions and issues unanswered 
and unresolved.
Translational research and translational effective-
ness unquestionably signify together a positive future 
for patients and stakeholders across the health sciences. 
Translational research utilizes laboratory protocol of 
basic biology and physiology on specific biopsies to bet-
ter define and characterize the pathological mechanisms 
that underlie the patient’s condition. Translational effec-
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effectiveness research and meta-analysis protocols and 
systematic review reports to craft and establish the con-
sensus of the best evidence base (BEB) for electing the 
most appropriate mode of therapeutic intervention to 
treat the patient’s condition [2–8].
Research synthesis, the chosen design for garnering 
BEB, is reported in the form of the systematic review. It 
is a systematic process of locating, and critically evaluat-
ing the body of research that addresses a particular clini-
cal issue. Systematic reviews yield the highest level and 
quality of evidence, and the consensus of BEB for efficacy 
(i.e., whether the treatment under study works under the 
controlled conditions of randomized controlled trials, 
RCTs), or effectiveness (i.e., benefits, costs, risks of the 
intervention real life situations). BEB can be expressed 
qualitatively, quantitatively, and statistically. Data extrac-
tion summarizes the salient evidence, sample size, nature 
of the individual studies, benefits and type and frequency 
of adverse events [2–10]. What remains under-studied is 
how best can comparative effectiveness research (CER) 
develop and validate a new research paradigm, referred 
to as “individual patient research (IPR)”, as opposed to 
the customary group research approach.
Case in point, translational science for healthcare con-
sists of a continuum simply described as translational 
research (T1), that is the transfer of knowledge from 
patient-centered basic research to the patient-targeted 
therapies. Translational effectiveness (T2), that identi-
fies BEB from peer-reviewed clinical research, including 
clinical trials and observational studies, and disseminates 
BEB to practice settings and communities of stakehold-
ers for the specific purpose of optimization of patient-
centered, and patient-targeted interventions. This 
two-fold approach clearly demands increased emphasis 
on improving IPR, as well as optimizing patient-clinician 
communication and patient-tailored care delivery [2, 3]. 
A third level of translational science (T3) could be con-
ceived to ensure quality improvement individual patient 
research (IPR) for community-based participatory and 
action research. This ultimate mode of translation will 
incorporate CER and patient-centered outcomes research 
and optimize dissemination and diffusion of innovations 
for the purpose of contributing to healthcare policies in 
primary care and community settings.
A sine qua non for patient-targeted therapies is to 
obtain patient-centered outcomes of research and evalu-
ation. That is to say, we must strive to tailor our research 
endeavors to the needs and characteristics of individual 
patients, rather than pursuing the traditional route of 
biostatistics that describes and makes inferences of group 
data. To foster patient centered research in healthcare, 
and as a direct product of the Affordable Care Act-2010, 
a novel Federal entity, the Patient-Centered Outcomes 
Research Institute (PCORI), was formed along side the 
existing National Institutes of Health (NIH) and the 
Agency for Healthcare Research and Quality (AHRQ). As 
it’s principal mandates, PCORI sets the methodological 
standards and guidelines in patient-centered outcomes 
research (i.e., individual patient research, IPR), prior-
itizes patient-centered outcomes research questions, 
obtains and disseminates BEB consensus, and responds 
to specific critiques, input and suggestions from the 
stakeholders.
One example of the use of IPR in translational health-
care is the model of temporomandibular joint disorder 
(TMJD). We outline here this timely and critical para-
digm for patient-targeted therapies in evidence-based 
medicine and evidence-based dentistry.
Arthrokinetic model of temporomandibular joint 
disorders (TMD)
The arthrokinetic reflex describes the way in which a 
typical joint movement can reflexively cause neuromus-
cular activation or inhibition [9, 10]. In the case of the 
jaw joint, the synovial articulation between the temporal 
and the mandibular bones, the complex osteo-anatomy is 
compounded by the powerful masticatory musculature 
and extensive motor and sensory (trigeminal, V3) inner-
vation [4, 11]. One unique feature of the joint is its unique 
articular disc composed of dense fibrous connective tis-
sue, which attaches to the joint capsule, a dense fibrous 
membrane that surrounds the joint and is connected to it 
by strong ligaments, and which is positioned between the 
two bones that form the joint, thus creating two distinct 
spaces. The disc is in fact a fibrous extension of the cap-
sule in between the two bones of the joint, which slides 
within the capsule during articulation of the joint driven 
by the neuro-musculature.
With age and trauma, the disc may become thin and 
undergo change of cartilage in the central part, changes 
that may lead to impaired movement of the joint. Among 
the most common disorder of the jaw joint is disc dis-
placement, which can lead to synovial inflammation, 
local pain and myalgias of the face, head, neck and shoul-
ders as well as migraine-type headaches. From the view-
point of translational research, jaw joint biopsies can be 
monitored for biomarkers of proximal (i.e., synovial) and 
distal inflammation (i.e., saliva, peripheral blood) (e.g., 
interleukin-6), and neurotransmitters of pain (e.g., sub-
stance P) [12, 13].
Clinical research and observations have described the 
wide spectrum of the arthrokinetic reflex in TMJD, medi-
ated largely by retrograde transport from the V3 terminal 
branch to the joint (auriculotemporal nerve) and the cen-
tral nervous system, and which can contribute and exac-
erbate neuro-muscular disorders, including tourette’s 
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syndrome, cervical dystonia, complex regional pain syn-
drome, gait or balance disorders, Parkinson’s disease, 
middle and inner ear dysfunction, impaired eye move-
ment, sleep disturbances, pain, and related neurological 
symptoms [13–15]. The context of sleep is particularly 
important because lack of quality sleep has been associ-
ated with increased risks of several health issues includ-
ing obesity, heart disease, and diabetes. Individual patient 
measures of sleep quality should include the patient’s 
quality of sleep that can be assessed with a polysomnog-
raphy in an experimental sleep study, and confirmed with 
the two critical blood or salivary biomarkers, oxalic acid 
and diacylglycerol 36:3, whose levels decrease signifi-
cantly following sleep deprivation and normalize upon 
sleep recovery [16], and functional MRI (fMRI).
As proof of concept, the overarching arthrokinetic 
reflex in TMJD, the working hypothesis can be tested that 
by expanding the joint anatomical space the arthroki-
netic reflex is reduced. In the context of patient-centered 
translational research, a broad spectrum of clinical inde-
pendent patient data can be obtained from patients diag-
nosed clinically, by palpation as well as imaging (X-rays, 
CT) with mild-severe TMJD. Salivary and synovial lev-
els of pro-inflammatory cytokines, replicate the findings 
reported in the literature [12], and are found to cor-
relate with significant impairments (p  <  0.05) in neuro-
psychological testing (e.g., Brief Visuospatial Memory 
Test, Grooved Pegboard, Hopkins Verbal Learning Test, 
Stroop), Polysomnography and fMRI (Fig. 1), in the state 
of jaw joint space constriction, compared to when the 
joint space is expanded.
Randomized cluster‑wedge clinical trial for TMD 
interventions
These observations strongly support the need to conduct 
patient-targeted therapy clinical trials to test the effi-
cacy and the effectiveness of the intervention designed 
to expand jaw joint space as a potential treatment for 
TMJD, and more broadly for the plethora of pathologies 
related to the jaw joint arthrokinetic reflex. It is impor-
tant to note that the intervention must be tailor-made for 
each patient along five principal criteria listed below and 
shown in Fig. 2:
  • Height
  • Pitch
  • Yaw
  • Roll
  • Anterior/posterior
We have proposed elsewhere [17, 18] the potential 
advantages of an adaptive cluster randomized stepped 
wedge blinded controlled trial, that would involve 
sequential roll-out of the intervention in a crossover par-
adigm. This would allow the different clusters (i.e., ambu-
latory clinics of a practice-based research network) to 
cross over and switch treatments at different time points. 
The first time point would yield baseline measurements 
for each patient individually, as none of the clusters 
would be receiving the experimental intervention. Within 
each cluster, patients will be randomized, thus yielding 
a cluster randomized stepped wedge blinded controlled 
trial. In a design such as this, all patients eventually 
Fig. 1 fMRI scans of one representative patient with constricted (a) or expanded jaw joint space (b). Expansion of the joint space is obtained as 
describe below
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receive the intervention, ensuring adequate power, equi-
poise as well as benefit- and cost-effectiveness.
Individual patient outcome data could include salivary 
and synovial pro-inflammatory cytokines and pain pep-
tides, as reported [12]. Related IPR measures could also 
include altered fMRI scans, and neuro-psychological 
testing, as our preliminary observations suggest.
Repeated individual patient outcome measures should 
be collected in the same manner as baseline every 
3  months for 9–12  months, depending on individual 
patient’s clinical progress. At subsequent time points, 
clusters will switch over, following random ordering, 
and measurements would be obtained from each patient 
and analyzed as deltas (∆: difference from baseline). That 
is to say, the data of the proposed study would be—for 
each individual patient—the set of deltas for each vari-
able repeated measures. Analysis of these data would fol-
low the routine repeated measure ANOVA process, with 
Newman-Keuls post hoc comparisons and Bonferroni 
corrections for comparative purposes, and hierarchical 
multiple regression for predictive purposes integrating 
other individual patient characteristics. If the data were 
expressed as ratio change from baseline, then individual 
patient data meta-analysis could be projected with an 
approach similar to the present use of odds ratios in cus-
tomary meta-analysis [2, 3, 6–8].
Implications for patient‑targeted therapies
This section on patient-targeted therapies of the Journal 
of Translational Medicine must redouble its focus on 
translational research (i.e., T1) investigations, on studies 
that pertain to translational effectiveness (i.e., T2; com-
parative effectiveness research), or on research that seeks 
to better define and characterize the T1–T2 transaction 
(i.e., T3). Here, we proposed a model by discussing the 
use of an adaptive cluster randomized stepped wedge 
blinded controlled trial to test a patient-targeted inter-
vention designed to ameliorate symptomatology and 
pathology derived from the arthrokinetic reflex of tem-
poromandibular joint disorder.
It is timely and critical that patient-targeted therapies 
be examined and tested through the critical lens of trans-
lational research, and of translational effectiveness. It is 
just as timely and critical that the best available evidence 
that derives from such translational science studies be 
efficiently disseminated to clinicians for the ultimate ben-
efit of individual patient and of all stakeholders.
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